Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

被引:645
|
作者
Beck, Kimberly E.
Blansfield, Joseph A.
Tran, Khoi Q.
Feldman, Andrew L.
Hughes, Marybeth S.
Royal, Richard E.
Kammula, Udai S.
Topalian, Suzanne L.
Sherry, Richard M.
Kleiner, David
Quezado, Martha
Lowy, Israel
Yellin, Michael
Rosenberg, Steven A.
Yang, James C.
机构
[1] NCI, Surg Branch, NIH, CRC, Bethesda, MD 20892 USA
[2] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA
[3] Medarex Inc, Princeton, NJ USA
关键词
D O I
10.1200/JCO.2005.04.5716
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) is an inhibitory receptor on T cells. Knocking out CTLA4 in mice causes lethal lymphoproliferation, and polymorphisms in human CTLA4 are associated with autoimmune disease. Trials of the anti-CTLA4 antibody ipilimumab (MDX-010) have resulted in durable cancer regression and immune-mediated toxicities. A report on the diagnosis, pathology, treatment, clinical outcome, and significance of the immune-mediated enterocolitis seen with ipilimumab is presented. Patients and Methods We treated 198 patients with metastatic melanoma (MM) or renal cell carcinoma (RCC) with ipilimumab. Results The overall objective tumor response rate was 14%. We observed several immune mediated toxicities including dermatitis, enterocolitis, hypophysitis, uveitis, hepatitis, and nephritis. Enterocolitis, defined by grade 3/4 clinical presentation and/or biopsy documentation, was the most common major toxicity (21% of patients). It presented with diarrhea, and biopsies showed both neutrophilic and lymphocytic inflammation. Most patients who developed enterocolitis responded to high-dose systemic corticosteroids. There was no evidence that steroid administration affected tumor responses. Five patients developed perforation or required colectomy. Four other patients with steroid-refractory enterocolitis appeared to respond promptly to tumor necrosis factor alpha blockade with infliximab. Objective tumor response rates in patients with enterocolitis were 36% for MM and 35% for RCC, compared with 11% and 2% in patients without enterocolitis, respectively (P =.0065 for MM and P =.0016 for RCC). Conclusion CTLA4 seems to be a significant component of tolerance to tumor and in protection against immune mediated enterocolitis and these phenomena are significantly associated in cancer patients.
引用
收藏
页码:2283 / 2289
页数:7
相关论文
共 50 条
  • [21] Identification of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) isoforms in the Pekin duck
    Yao, Qingxia
    Fischer, Karl P.
    Motyka, Bruce
    Ferland, Sean
    Li, Lena
    Tyrrell, D. Lorne
    Gutfreund, Klaus S.
    DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, 2010, 34 (07): : 749 - 758
  • [22] Mediterranean fever gene mutations: correlation with cytotoxic T-lymphocyte-associated antigen 4 gene polymorphism
    El Hawary, Rabab
    Elanwary, Sherif
    Meshaal, Safa
    MICROBIOLOGY AND IMMUNOLOGY, 2015, 59 (03) : 160 - 165
  • [23] What Is the Role of Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?
    Robert, Caroline
    Ghiringhelli, Francois
    ONCOLOGIST, 2009, 14 (08): : 848 - 861
  • [24] Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade Insights into Pathogenesis from an Autopsy Series
    Caturegli, Patrizio
    Di Dalmazi, Giulia
    Lombardi, Martina
    Grosso, Federica
    Larman, H. Benjamin
    Larman, Tatianna
    Taverna, Giacomo
    Cosottini, Mirco
    Lupi, Isabella
    AMERICAN JOURNAL OF PATHOLOGY, 2016, 186 (12): : 3225 - 3235
  • [25] Increased level of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule (sCTLA-4) in patients with multiple sclerosis
    Pawlak, E.
    Bilinska, M.
    Frydecka, I.
    Podemski, R.
    Ciszak, L.
    Kosmaczewska, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 123 - 123
  • [26] Cytotoxic T-Lymphocyte-Associated Antigen 4 Gene Polymorphisms in Japanese Children with Infection-Associated Hemophagocytic Lymphohistiocytosis
    Yoshiyama, Megumi
    Kounami, Shinji
    Nakayama, Keiko
    Okutani, Takahiro
    Aoyagi, Noriyuki
    Yoshikawa, Norishige
    ACTA HAEMATOLOGICA, 2010, 123 (03) : 186 - 190
  • [27] Cytotoxic T-lymphocyte-associated antigen-4 single nucleotide polymorphisms and haplotypes in primary biliary cirrhosis
    Donaldson, Peter
    Veeramani, Sivakumar
    Baragiotta, Anna
    Floreani, Annarosa
    Venturi, Carla
    Pearce, Simon
    Wilson, Valerie
    Jones, David
    James, Oliver
    Taylor, John
    Newton, Julia
    Bassendine, Margaret
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (06) : 755 - 760
  • [28] Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
    Hodi, FS
    Mihm, MC
    Soiffer, RJ
    Haluska, FG
    Butler, M
    Seiden, MV
    Davis, T
    Henry-Spires, R
    MacRae, S
    Willman, A
    Padera, R
    Jaklitsch, MT
    Shankar, S
    Chen, TC
    Korman, A
    Allison, JP
    Dranoff, G
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (08) : 4712 - 4717
  • [29] Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma - A new cause of uveitis
    Robinson, MR
    Chan, CC
    Yang, JC
    Rubin, BI
    Gracia, GJ
    Sen, HN
    Csaky, KG
    Rosenberg, SA
    JOURNAL OF IMMUNOTHERAPY, 2004, 27 (06) : 478 - 479
  • [30] Tumor regression and autoimmunity in cytotoxic T lymphocyte-associated antigen 4 blockade-treated patients
    Weber, JS
    ANNALS OF SURGICAL ONCOLOGY, 2005, 12 (12) : 957 - 959